Fluorescent Caspase-1 Probes for Intestinal Barrier Dysfunction Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively detect cell-barrier dysfunctions associated with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), which are often linked to abnormal intestinal epithelial cell extrusions, leading to diagnostic challenges and inadequate treatment approaches.
Innovation Solution
A method involving staining patient intestinal, oropharyngeal, or buccal epithelial cells with a probe conjugated to a caspase-1 inhibitor and analyzing the fluorescence levels to detect elevated caspase-1 levels, which indicate cell-barrier dysfunction, using techniques like fluorescence microscopy or confocal laser endomicroscopy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then general screening is possible, but detection precision for cell-barrier dysfunction is insufficient
Solution Approach 1:
The patent employs fluorescent probes that emit detectable signals when bound to caspase-1, enabling visual detection and quantification of cell-barrier dysfunction through fluorescence intensity changes. This allows precise measurement of caspase-1 levels in epithelial cells without requiring complex biochemical assays.
Solution Approach 2:
The patent replaces complex mechanical or biochemical extraction and analysis systems with optical detection methods. By using fluorescently labeled caspase-1 inhibitors, the system substitutes elaborate laboratory procedures with straightforward fluorescence microscopy or flow cytometry analysis, maintaining high precision while reducing operational complexity.
2Measurement precision
If intestinal biopsies are obtained for diagnosis, then accurate detection is possible, but patient discomfort and procedural complexity increase
Solution Approach 1:
The patent develops fluorescent probes that can detect caspase-1 activity across multiple epithelial cell types and locations (intestinal, oropharyngeal, buccal). This universality allows the same diagnostic approach to work with samples from different anatomical sites, enabling less invasive sampling methods while maintaining diagnostic accuracy.
Solution Approach 2:
The patent uses fluorescently labeled caspase-1 inhibitors as intermediary molecules that can penetrate epithelial cells and bind to active caspase-1. These intermediaries enable detection of intracellular caspase-1 activity without requiring cell lysis or complex extraction procedures, simplifying the diagnostic workflow while preserving measurement accuracy.
3Measurement precision
If caspase-1 levels are measured to detect cell-barrier dysfunction, then diagnostic accuracy improves, but treatment guidance capability was previously insufficient
Solution Approach 1:
The patent establishes a feedback loop where fluorescent measurement of caspase-1 levels provides quantitative data that directly guides treatment decisions. The degree of fluorescence intensity correlates with caspase-1 activity levels, which in turn indicates the severity of cell-barrier dysfunction and helps determine appropriate treatment intensity and duration.
Solution Approach 2:
The patent utilizes changes in fluorescence signal parameters (intensity, distribution pattern) to monitor caspase-1 activity dynamics. By tracking these parameter changes over time or in response to treatment, the system provides versatile guidance for treatment selection, dose adjustment, and efficacy monitoring, transforming a static diagnostic measurement into a dynamic treatment guidance tool.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate diagnosis of IBS and IBD by identifying elevated caspase-1 levels in epithelial cells, providing a basis for treatment with caspase-1 inhibitors, anti-inflammatory agents, or probiotics, and indicating intestinal cell barrier dysfunction through gap density analysis.
Implementation Method 1
staining patient intestinal, oropharyngeal, or buccal epithelial cells with a probe having a detectable marker conjugated to a caspase-1 inhibitor... examining the stained intestinal, oropharyngeal, or buccal epithelial cells for the presence of elevated levels of detectable marker
Implementation Method 2
probe-based confocal laser endomicroscopy (pCLE)... viewing by probe-based confocal laser endomicroscopy (pCLE)
Implementation Method 3
The cells are stained in situ, and viewed by probe-based confocal laser endomicroscopy (pCLE)
Data Source
Figure 1A-1~1C-2
Figure 2A~2C-3
Figure 3A~3D
AI summary
Methods for detecting intestinal cell barrier dysfunction in a patient are disclosed. In one method, patient intestinal epithelial cells (lECs), oropharyngeal epithelial cells (OECs) or buccal epithelial cells (BECs) are stained with detectable probes specific against caspase-1 and caspase-3&7, and the cells are viewed for the presence of elevated levels of caspase-1, as evidence by a significantly higher ratio of caspase-1 marker to caspase-3&7, as an indicator of cell barrier dysfunction. In a second method, in situ images of a patient's lEC's, OECs or BECs are obtained by probe-based confocal laser endomicroscopy (pCLE), and images are analyzed for density of cell gaps. Also disclosed is a probe composition for use in detecting intestinal cell barrier dysfunction.